Carmen Mora

ORCID: 0000-0003-1570-6332
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Parathyroid Disorders and Treatments
  • Chronic Kidney Disease and Diabetes
  • Dialysis and Renal Disease Management
  • Genetic Syndromes and Imprinting
  • Advanced Glycation End Products research
  • Adipokines, Inflammation, and Metabolic Diseases
  • Magnesium in Health and Disease
  • Erythropoietin and Anemia Treatment
  • Blood Pressure and Hypertension Studies
  • Diabetes and associated disorders
  • Muscle and Compartmental Disorders
  • Kruppel-like factors research
  • Fibroblast Growth Factor Research
  • Pancreatitis Pathology and Treatment
  • Renal Diseases and Glomerulopathies
  • Diabetes Treatment and Management
  • Vitamin D Research Studies
  • Anesthesia and Pain Management
  • Pharmacological Effects and Toxicity Studies
  • Pain Management and Opioid Use
  • Central Venous Catheters and Hemodialysis
  • Systemic Sclerosis and Related Diseases
  • Cardiovascular Health and Disease Prevention
  • Public Health and Environmental Issues
  • Iron Metabolism and Disorders

Hospital Universitario Nuestra Señora de Candelaria
2016-2025

Instituto de Salud Carlos III
2013-2025

Sociedad Española de Nefrología
2013-2024

RELX Group (United States)
2023

Universidad de Los Andes
2020-2022

ORCID
2020

Hospital de Especialidades
2012-2019

Mexican Social Security Institute
2019

Montrose Center
2017

Hospital Universitario Son Espases
2011-2016

Diabetic kidney disease (DKD) is the leading cause of ESRD. We conducted an open-label, prospective, randomized trial to determine whether pentoxifylline (PTF), which reduces albuminuria, in addition renin-angiotensin system (RAS) blockade, can slow progression renal patients with type 2 diabetes and stages 3–4 CKD. Participants were assigned receive PTF (1200 mg/d) (n=82) or a control group (n=87) for years. All received similar doses RAS inhibitors. At study end, eGFR had decreased by...

10.1681/asn.2014010012 article EN Journal of the American Society of Nephrology 2014-06-27

<i>Background:</i> Recent studies have shown a role for inflammation in the pathogenesis of diabetic nephropathy (DN). Tumor necrosis factor (TNF)-α, interleukin (IL)-1 and IL-6 are cytokines with prevalent pro-inflammatory activity. Our objective was to study renal gene expression TNF-α, IL-1 DN their relationship damage assessed by urinary albumin excretion (UAE). In addition, we also investigated effect angiotensin-converting enzyme inhibition pentoxifylline (PTF)...

10.1159/000098004 article EN American Journal of Nephrology 2006-01-01

Klotho is involved in vascular health. We aimed to analyse a cross-sectional study the relationship between and human coronary artery disease (CAD).The included 371 subjects who underwent angiography 70 patients elective cardiac surgery recruited May 2008 June 2009. The presence severity (stenosis index) of CAD, cardiovascular risk factors, gene expression thoracic aorta, serum soluble concentrations were evaluated.The concentration was lower (p<0.001) with significant CAD (n=233). maximal...

10.1136/heartjnl-2013-304746 article EN Heart 2013-10-28

Background. Inflammation is a potential factor in the development and progression of diabetic nephropathy. The aim this study was to analyse relationship between pro-inflammatory cytokine tumour necrosis factor-α (TNFα) clinical markers glomerular tubulointerstitial damage [urinary albumin excretion (UAE) urinary N-acetyl-β-glucosaminidase (UNAG), respectively] large group type 2 patients.

10.1093/ndt/gfl469 article EN Nephrology Dialysis Transplantation 2006-08-26

Despite the beneficial effects of blockade renin-angiotensin system in diabetic nephropathy (DN), albuminuria and progression renal disease are not completely halted by these agents. Therefore, it is necessary to explore potential antiproteinuric renoprotective innovative therapeutic approaches. This study tested hypothesis that combination pentoxifylline (PTF) with angiotensin II receptor blockers normotensive patients type 2 diabetes produces an additive effect. Sixty-one DN residual...

10.1681/asn.2005010001 article EN Journal of the American Society of Nephrology 2005-05-26

Mineral metabolism abnormalities and inflammation are concerns in chronic kidney disease (CKD). Interrelationships among these parameters have not been analyzed.The study included 133 patients with CKD on dialysis receiving calcium (Ca) supplements, phosphate binders, or vitamin D. Estimated GFR (eGFR) was 34.1 +/- 6.8 ml/min/1.73 m(2); 107 participants had stage 3 CKD, 26 4.Patients were classified by tertiles of Ca, phosphorus (P), Ca-P product (Ca x P), parathyroid hormone (PTH). After...

10.2215/cjn.02420409 article EN Clinical Journal of the American Society of Nephrology 2009-09-25

Hyperphosphatemia and subclinical endotoxemia are important sources of inflammation in HD. Proinflammatory cytokines strong correlates soluble CD14 (sCD14) concentrations, an independent predictor mortality this population. We evaluated the effects calcium acetate sevelamer hydrochloride on serum inflammatory profile, endotoxin sCD14 levels HD patients.Prospective, randomized, open-label, parallel design trial. Fifty-nine stable patients, 30 receiving sevelamer, 29 were evaluated. Serum...

10.2215/cjn.01650211 article EN Clinical Journal of the American Society of Nephrology 2011-07-23
Coming Soon ...